SOUL Trial: Oral Semaglutide and MACE Reduction Cardiovascular protection from an oral GLP-1 in high-risk type 2 diabetes. d [Internet]. 2026 Jul. 7 [cited 2026 Jul. 28];4(19):38-9. Available from: https://thediabzen.com/index.php/d/article/view/62